Product Name: Doxorubicin hydrochloride
CAS: 25316-40-9
MF: C27H30ClNO11
MW: 579.98
EINECS: 246-818-3
punctum liquescens: 216 °C (dec.)(lit.)
Repono temp.: 2-8°C
Doxorubicin praesto est ac dosage forma conventionalis et praeparatio liposomalis, quorum utrumque administratur infusione. Doxorubicin HCl pulveris praesto est in10-, 20-, 50-, et phialas 150-mg et late in carcinomate tractando, comprehendo leukemias, mollis et os texturisarcomas, Wilms tumore, neuroblastoma, cellula parva lungcancer, et cancri ovarii et testium.
Doxorubicin est antitumor anthracyclinus antibioticus qui DNA topoisomerase II vetat duplices subductis DNA erumpit.. By intercalating within DNA, doxorubicin inhibits nucleic acid synthesis and induces apoptosis by inducing the accumulation of the p53 tumor suppressor protein.
It is commonly used in the treatment of a wide range of cancers, including hematological malignancies (blood cancers, like leukaemia and lymphoma), many types of carcinoma (solid tumours) and soft tissue sarcomas.It is often used in combination chemotherapy as a component of various chemotherapy regimens.
| Items Exertus |
Specification |
Proventus |
| Puritas |
98.0~102.0% |
99.02% |
| Descriptio |
Orange-red or red crystalline powder; No visible
evidence of contamination by foreign matter. |
Confirm |
| Lepidium sativum |
IR spectrum corresponds to the IR spectrum of the reference standard |
Confirm |
| Lepidium sativum B * |
The retention time of the doxorubicin peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, sicut adeptus est in primordio. |
Confirm |
| Solubilitas |
Soluble in water and methanol; leviter solutum in ethanol; prope insolubilem in acetone. |
Conforms |
| RELICTUM Solvents |
|
|
| Acetone |
≤ 0.5% |
0.31% |
| Acetone +Ethanol |
≤ 2.5% |
0.60% |
| methanolum |
≤ 0.3% |
Non detectum |
| Dichloromethane |
≤ 0.06% |
Non detectum |
| pH* |
4.0 to 5.5 |
5.1 |
| Aqua Content |
≤ 4.0% |
0.8% |
| Substantiae cognatae |
|
|
| immunditiam A (Doxorubicinone) |
≤ 0.5% |
0.1% |
| Alia alia ignota immunditia |
≤ 0.1% |
0.07% |
| Totalis ignotis immunditiis |
≤ 0.3% |
0.2% |
| Totalis immunditias |
≤ 1.0% |
0.9% |
| conclusio |
Prosequitur vexillum referat |
